Evaluating the Pros and Cons of State Psychedelic Task Forces
Across the United States, a quiet but profound shift is occurring within the halls of state legislatures. As the federal government continues to weigh the potential reclassification of breakthrough mental health therapies using psilocybin and MDMA, individual states are taking matters into their own hands. Just this year alone,106 psychedelics-related bills have been filed across 16 states with an additional four proposed psychedelics bills filed by federal lawmakers.
Faced with an ongoing mental health crisis and a growing body of clinical research pointing to the efficacy of psychedelic-assisted therapies, lawmakers are increasingly turning to a familiar legislative tool to navigate this uncharted territory: the state-level task force.
On the surface, the establishment of a psychedelic task force represents a prudent, bipartisan approach to complex drug policy reform. These working groups are explicitly designed to bring together medical professionals, law enforcement officials, legal experts, and patient advocates to thoroughly study the implications of decriminalization or therapeutic legalization. However, as the initial wave of these task forces begins to conclude their work and present their findings, a more complicated reality is emerging that highlights how some task forces fail.
Effective Task Forces in Hawaii and Minnesota
Ultimately, state-level psychedelic task force reports are little more than recommendations to the state’s legislature. While they can be put together thoughtfully and the policies laid out can reflect the best available data, there is no guarantee that the state legislature will consider task force reports when crafting new legislation. In fact, some reports simply sit on shelves gathering dust, leaving advocates frustrated and patients waiting for care.
Despite these limitations, task force reports have helped state legislatures navigate policy reforms that impact the use of psychedelics. This is especially true in states where expansive, direct legalization proposals fall short a few years in a row for similar reasons, as has recently been seen in Hawaii.
In the Aloha State, lawmakers recognized the vital need for a localized, methodical approach before committing to broad legalization. A Hawaii House committee has unanimously advanced a Senate-passed bill to establish a “Mental Health Emerging Therapies Task Force.” This proposed task force would spend two full years comprehensively reviewing scientific literature around clinical research, and developing concrete policy recommendations for the safe, ethical implementation of psychedelic therapies using substances such as psilocybin and MDMA.
Aimed squarely at addressing the state’s urgent mental health crisis – particularly among vulnerable populations such as military veterans, trauma survivors, and first responders – the legislation proactively prepares Hawaii’s public health systems for potential future federal rescheduling of these breakthrough therapies by the U.S. Food and Drug Administration.
The Hawaii House Health Committee advanced the bill with a few critical amendments on March 23, notably shifting the oversight of the task force from the state Department of Health directly to the John A. Burns School of Medicine at the University of Hawaii. The amendments also carefully clarify the state Department of Law Enforcement’s role in seamlessly aligning state scheduling if federal drug classifications change. The bill has received robust, supportive testimony from both the state Department of Health and the governor’s Office of Wellness and Resilience.
If enacted into law, it will organically build upon the exploratory work of a prior state task force back in 2023, contrasting heavily with separate, broad marijuana legalization proposals that have recently stalled in the state’s legislature for the current year. Most recently, the bill was referred to the Hawaii’s Department of Health and Human Services where it is awaiting further review.
A similar, albeit more advanced, scenario is currently unfolding in the midwest. In January 2025, Minnesota’s Psychedelic Medicine Task Force officially submitted its comprehensive report to the state legislature, definitively recommending the creation of a state-regulated clinical program for psychedelic medicines. Chaired by neuroscientist Jessica Nielson, the task force explicitly suggested decriminalizing the personal use and possession of certain psychedelics while simultaneously allocating more state funding for empirical research into their tangible health benefits.
Drawing inspiration from pioneering access programs already established in states like Oregon and Colorado, the Minnesota task force emphasizes that strict regulation and clinical oversight are the safest paths forward for the general public. While the extensive report intentionally stops short of recommending full recreational legalization, Nielson highlighted that a regulated framework is entirely necessary for basic harm reduction and to effectively prevent the public from consuming dangerous, unregulated synthetic products that have flooded illicit markets. Having successfully completed its official administrative duties, the task force has now shifted its primary focus to broader public education.
Ultimately, the monumental decision to implement these progressive guidelines currently rests with the Minnesota state legislature.Minnesota lawmakers appear to be listening closely. On March 9, members of the Minnesota House Health Finance and Policy Committee advanced a bipartisan bill to officially legalize the regulated therapeutic use of psilocybin for adults 21 and older, while also proposing to reclassify the psychedelic from Schedule I to Schedule IV under state law.
Sponsored by Rep. Andy Smith, and approved by a key House committee, the legislation would systematically establish a pilot program allowing up to 1,000 qualified patients to receive supervised, psilocybin-assisted therapy for severe mental health conditions like post-traumatic stress disorder and treatment-resistant depression.
With robust oversight from the Minnesota Department of Health and the Office of Cannabis Management, the proposed program would formally license facilitators to provide comprehensive care in approved clinical or residential settings. The ultimate goal is to create a safe, meticulously state-regulated framework for psychedelic medicine as the bill boldly moves forward for further legislative and funding review. Up next for Minnesota’s medical-first bill is another hearing in front of the Minnesota House’s Commerce, Finance, and Policy Committee on Wednesday, April 15th.
Task Force Roadblocks In Maryland
Not all states are experiencing a positive forward momentum from task force recommendations to actionable legislation. In Maryland, a recent legislative move to extend the timeline of the state’s Task Force on Responsible Use of Natural Psychedelic Substances has sparked significant debate regarding the true utility of these advisory commissions. While some view the formal extension as a necessary step for thorough evaluation, critics – like Prince George County, Maryland resident Jason Ziegler – argue that the state’s task force is merely a political stall tactic designed to avoid tough votes.
“I think the bill comes from a place of good intention, but in practice it risks delaying real progress toward what many people ultimately want to see, which is the destigmatization of plant medicine and broader responsible access,” said Ziegler, the founder of Paradise Farmers Market DC – a harm reduction and psychedelic education organization that’s been monitoring the Maryland legislation. “At this point, there is already a growing body of research and real-world policy examples that demonstrate the therapeutic potential of these substances.”
Ziegler emphasized that the continuous cycle of state-sponsored studying can inadvertently become an enemy of tangible progress. “Continuing to study the issue is valuable, but extending the task force indefinitely could slow the momentum around meaningful reform,” he noted. “Maryland has an opportunity to move beyond simply discussing these substances and begin thinking about how to responsibly integrate them into a framework that prioritizes safety, education, and access for those who could benefit.”
As for what he’d like to see definitively included in a more expansive, forward-thinking policy framework, Ziegler said the first things he would like to see is the deprioritization criminal prosecution of psychedelics and the eventual decriminalization of entheogens as a whole.
“The data increasingly shows that these plants and fungi have relatively low harm profiles,” Ziegler said. , “While the potential therapeutic benefits are significant. The conversation should shift toward education, harm reduction, and responsible use rather than criminalization.”
Advocates argue that continuing to criminalize users who are desperately seeking alternative treatments for severe depression or cluster headaches serves no measurable public safety interest. “The second major step,” Ziegler added, “would be developing an evolving therapeutic framework that Maryland can begin moving toward sooner rather than later.”
“We already have working examples in places like Colorado, Oregon, and even overseas that demonstrate how regulated models can operate responsibly. Maryland has an opportunity to learn from those examples and build a structure that prioritizes patient safety, proper training, and accessibility within a controlled environment.” Ziegler concluded.
Maryland Shows What Lawmakers Need From Task Forces
According to some advocates, a glaring disconnect between what advocates want and what legislators are actually willing to pass remains the central, structural challenge of the task force model. Sam Chapman, the Founder and Executive Director of the Center for Psychedelic Policy, offered a blunt, pragmatic assessment of why so many comprehensive task force reports ultimately fail to translate into actual state law. Having successfully managed the historic campaign for Oregon’s Measure 109 – the nation’s first licensed and regulated psilocybin therapy program – Chapman understands the intricate political calculus required to move the needle in state capitols.
The work of the panel of experts — formally titled the Maryland Task Force On Responsible Use of Natural Psychedelic Substances —highlights some of the priorities that need to be followed for a report to produce the desired outcome. “Maryland’s task force has put in serious work, and it shows,” said Chapman. “But the truth is, this report was written for the advocates, when it should have been written for legislators. Legislators need to be able to find the front door. They need a clear, narrow ask, incremental steps, and draft bill language.”
According to Chapman, overwhelming lawmakers with overly ambitious proposals is a reliable recipe for legislative failure. “When a task force recommends three substances, multiple access pathways launching simultaneously, and the original bill includes exploring online sales and home delivery of psychedelic substances, something that has literally never been done, that’s asking someone who just learned to swim to jump off the high dive,” he explained. “You’ve given every cautious legislator a perfectly rational reason to kick the can down the road.”
Despite the frustrating delays and bureaucratic hurdles, Chapman maintains that the task force model can still be a highly effective vehicle for reform if appropriately leveraged by its participants. “Advocates who are frustrated by the extension are looking at this the wrong way,” Chapman noted. “A task force with bipartisan support, strong legislative sponsors, and an October reporting deadline is a runway, not a roadblock. But we don’t need that time spent producing another 200 pages restating what the clinical research already tells us.”
Instead, Chapman advocates for a laser-focused approach that speaks directly to the fiscal and public health concerns of the lawmakers actively holding the pen. “What’s missing is the translation work: one substance (psilocybin), a handful of conditions where the clinical evidence is strongest, a compelling efficacy case showing psilocybin therapy produces better outcomes than what the state of Maryland is currently offering those patients, and an economic case showing the state what it’s already spending on them and what psilocybin therapy could deliver for less. That’s what moves legislation.”
In the end, the varying task forces currently operating across the country represent a critical, albeit unpredictable, transitional phase in the broader psychedelic renaissance. As more states look to cautiously avoid the structural pitfalls of the chaotic early days of cannabis legalization, the methodical, highly regulated approach of a designated commission remains attractive to moderate lawmakers.
“Most states would love to have what Maryland has. A governor who’s engaged, bipartisan support, and Johns Hopkins right there in Baltimore,” Chapman said. “The lesson for Maryland isn’t to slow down. It’s to stop trying to eat the whole elephant in one bite, and narrow the target.”
Whether in Hawaii, Minnesota, or Maryland, the true effectiveness of a psychedelic task force may not be based on the thickness of its final printed report or the sheer breadth of its scientific review. Rather, it may well be determined by the specific, pragmatic legislative action that immediately follows. Commissions that successfully draft highly targeted, economically sound, and politically viable legislation, will reduce the risk of remaining purely academic exercises in states desperately seeking real-world public health solutions.
As for what’s next in Maryland, the psychedelic task force extension bill was just sent to the governor’s desk and is expected to be signed later this month.